Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
To determine whether fondaparinux as monotherapy without warfarin is effective and safe for
long-term (90 days) treatment of DVT and/or PE, thus gaining new long-term experience and
data using fondaparinux.